{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:03:14Z","timestamp":1791216194270,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.2515\/therapie\/2010055","type":"journal-article","created":{"date-parts":[[2010,12,10]],"date-time":"2010-12-10T13:35:52Z","timestamp":1291988152000},"page":"429-437","source":"Crossref","is-referenced-by-count":5,"title":["Traitement symptomatique de la maladie d\u2019Alzheimer et perspectives th\u00e9rapeutiques"],"prefix":"10.1016","volume":"65","author":[{"given":"Fran\u00e7oise","family":"Forette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Hauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.2515\/therapie\/2010055_bb0005","series-title":"Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database of Systematic Reviews","author":"Birks","year":"2006"},{"key":"10.2515\/therapie\/2010055_bb0010","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jama.289.2.210","article-title":"Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis","volume":"289","author":"Trinh","year":"2003","journal-title":"JAMA"},{"key":"10.2515\/therapie\/2010055_bb0015","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.1532-5415.2005.53313.x","article-title":"Caregiver-specific outcomes in antidementia clinical drug trials: a systematic review and meta-analysis","volume":"53","author":"Lingler","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"10.2515\/therapie\/2010055_bb0020","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1185\/030079905X56565","article-title":"Rivastigmine and donepezil treatement in moderate to moderately severe Alzheimer\u2019s disease over a 2-year period","volume":"21","author":"Bullock","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.2515\/therapie\/2010055_bb0025","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jnnp.72.3.310","article-title":"Cholinesterase inhibitor treatment alters the natural history of Alzheimer\u2019s disease","volume":"72","author":"Lopez","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.2515\/therapie\/2010055_bb0030","first-page":"236","article-title":"Amnestic MCI or prodromal Alzheimer\u2019s disease?","volume":"44","author":"Dubois","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.2515\/therapie\/2010055_bb0035","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000102568","article-title":"Memantine in moderate to severe Alzheimer\u2019s disease: a meta-analysis of randomized clinical trials","volume":"24","author":"Windblad","year":"2007","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.2515\/therapie\/2010055_bb0040","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(04)16499-4","article-title":"AD2000 Collaborative Group. Long term donepezil treatment in 565 patients with Alzheimer\u2019s disease (AD2000): randomized double-blind trial","volume":"363","author":"Courtney","year":"2004","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2010055_bb0045","series-title":"Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer\u2019s disease. NICE guidance TA11","author":"National Institute for health and Clinical Excellence (NICE)","year":"2006"},{"key":"10.2515\/therapie\/2010055_bb0050","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jama.291.3.317","article-title":"Memantine study group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donezepil: a randomized controlled trial","volume":"291","author":"Tariot","year":"2004","journal-title":"JAMA"},{"key":"10.2515\/therapie\/2010055_bb0055","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/jnnp.2008.158964","article-title":"Long term effect of the concomitant use of memantine cholinesterase inhibition in Alzheimer\u2019s disease","volume":"80","author":"Lopez","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.2515\/therapie\/2010055_bb0060","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0924-977X(00)00067-5","article-title":"Long-term efficacy and safety of donepezil in the treatment of Alzheimer\u2019s disease: final analysis of a US multicentre open-label study","volume":"10","author":"Rogers","year":"2000","journal-title":"Eur neuropsychopharmacol"},{"key":"10.2515\/therapie\/2010055_bb0065","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","article-title":"Alzheimer\u2019s disease","volume":"368","author":"Blennow","year":"2007","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2010055_bb0070","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1093\/brain\/awl280","article-title":"Therapeutic approaches to Alzheimer\u2019s disease","volume":"129","author":"Klafki","year":"2006","journal-title":"Brain"},{"key":"10.2515\/therapie\/2010055_bb0075","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/85059","article-title":"Mice deficient in BACE1, the Alzheimer betasecretase, have normal phenotype and abolished beta-amyloid generation","volume":"4","author":"Luo","year":"2001","journal-title":"Nat Neurosci"},{"key":"10.2515\/therapie\/2010055_bb0080","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1471-4159.2006.04260.x","article-title":"Oral administration of a potent and selective non peptidic BACE1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid beta production in vivo","volume":"100","author":"Hussain","year":"2007","journal-title":"J Neurochem"},{"key":"10.2515\/therapie\/2010055_bb0085","first-page":"383","article-title":"Progress toward a practical BACE-1 Inhibitor","volume":"4","author":"Hills","year":"2007","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.2515\/therapie\/2010055_bb0090","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.2165\/00003495-200666160-00004","article-title":"Disease-modifying therapies in Alzheimer\u2019s disease: how far have we come?","volume":"66","author":"Hull","year":"2006","journal-title":"Drugs"},{"key":"10.2515\/therapie\/2010055_bb0095","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00023210-200620050-00002","article-title":"Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer\u2019s disease: propects, limitations and strategies","volume":"20","author":"Evin","year":"2006","journal-title":"CNS Drugs"},{"key":"10.2515\/therapie\/2010055_bb0100","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/35074581","article-title":"New protease inhibitors prevent gamma-secretase production of Abeta 40\/42 without affecting Notch cleavage","volume":"3","author":"Petit","year":"2001","journal-title":"Nat Cell Biol"},{"key":"10.2515\/therapie\/2010055_bb0105","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/01.wnf.0000167360.27670.29","article-title":"Safety, tolerability, and changes in amyloid beta concentration after administration of a gamma-secretase inhibitor in volonteers","volume":"28","author":"Siemers","year":"2005","journal-title":"Clin neuropharmacol"},{"key":"10.2515\/therapie\/2010055_bb0110","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1073\/pnas.0403921101","article-title":"Therapeutic effects of PKC activators in Alzheimer\u2019s disease transgenic mice","volume":"101","author":"Etcheberrigaray","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.2515\/therapie\/2010055_bb0115","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.2515\/therapie\/2010055_bb0120","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/35050110","article-title":"Abeta peptide immunisation reduces behavioural impairment and plaques in a model of Alzheimer\u2019s disease","volume":"408","author":"Janus","year":"2000","journal-title":"Nature"},{"key":"10.2515\/therapie\/2010055_bb0125","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/35050116","article-title":"Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer\u2019s disease","volume":"408","author":"Morgan","year":"2000","journal-title":"Nature"},{"key":"10.2515\/therapie\/2010055_bb0130","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.2515\/therapie\/2010055_bb0135","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Ab\u00eata 42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"10.2515\/therapie\/2010055_bb0140","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1212\/01.WNL.0000159743.08996.99","article-title":"Effects of Abeta immunization (AN 1792) on MRI measures of cerebral volume in Alzheimer disease","volume":"64","author":"Fos","year":"2005","journal-title":"Neurology"},{"key":"10.2515\/therapie\/2010055_bb0145","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nm840","article-title":"Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report","volume":"9","author":"Nicoll","year":"2003","journal-title":"Nat Med"},{"key":"10.2515\/therapie\/2010055_bb0150","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/01.WNL.0000148590.39911.DF","article-title":"Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease","volume":"64","author":"Masliah","year":"2005","journal-title":"Neurology"},{"key":"10.2515\/therapie\/2010055_bb0155","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0896-6273(03)00294-0","article-title":"Antibodies against beta-amyloid slow cognitive decline in Alzheimer\u2019s disease","volume":"38","author":"Hock","year":"2003","journal-title":"Neuron"},{"key":"10.2515\/therapie\/2010055_bb0160","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.4049\/jimmunol.174.3.1580","article-title":"Prototype Alzheimer\u2019s disease vaccine using the immunodominant B cell epitope from beta amyloid and promiscuous T cell epitope pan HLA DR-binding peptide","volume":"174","author":"Agadjanyan","year":"2005","journal-title":"J Immunol"},{"key":"10.2515\/therapie\/2010055_bb0165","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1474-4422(04)00929-9","article-title":"Intravenous immunoglobulins for Alzheimer\u2019s disease","volume":"3","author":"Fillit","year":"2004","journal-title":"Lancet Neurology"},{"key":"10.2515\/therapie\/2010055_bb0170","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/jnnp.2003.033399","article-title":"Intravenous immunoglobulin containing antibodies against b\u00eata-amyloid for the treatment of Alzheimer\u2019s disease","volume":"75","author":"Dodel","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.2515\/therapie\/2010055_bb0175","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S1474-4422(03)00484-8","article-title":"Heparan sulphate proteoglycans in Alzheimer\u2019s disease and amyloid-related disorders","volume":"2","author":"Van Horssen","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.2515\/therapie\/2010055_bb0180","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/archneur.60.12.1685","article-title":"Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Ab\u00eata amyloid deposition and toxicity in Alzheimer disease: a pilot phase II clinical trial","volume":"60","author":"Ritchie","year":"2003","journal-title":"Arch Neurol"},{"key":"10.2515\/therapie\/2010055_bb0185","first-page":"1","article-title":"Tauopathie et maladie d\u2019Alzheimer, un processus d\u00e9g\u00e9n\u00e9ratif \u00e0 part enti\u00e8re","volume":"4","author":"Bu\u00e9e","year":"2006","journal-title":"Psychol Neuropsychiatr Vieil"},{"key":"10.2515\/therapie\/2010055_bb0190","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0165-0173(00)00019-9","article-title":"Tau proteins isoforms, phosphorylation and role in neurodegenerative disorders","volume":"33","author":"Bu\u00e9e","year":"2000","journal-title":"Brain Res Rev"},{"key":"10.2515\/therapie\/2010055_bb0195","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2174\/1389450043345254","article-title":"Inhibition of neurofibrillary degeneration: a promising approach to Alzheimer\u2019s disease and other tauopathies","volume":"5","author":"Iqbal","year":"2004","journal-title":"Curr Drug Targets"},{"key":"10.2515\/therapie\/2010055_bb0200","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1074\/jbc.M410984200","article-title":"Anthraquinones inhibit tau aggregation and dissolve Alzheimer\u2019s paired helical filaments in vitro and in cells","volume":"280","author":"Pickhardt","year":"2005","journal-title":"J Biol Chem"},{"key":"10.2515\/therapie\/2010055_bb0205","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molmed.2005.02.008","article-title":"Tau phosphorylation in Alzheimer\u2019s disease: pathogen or protector?","volume":"11","author":"Lee","year":"2005","journal-title":"Trends Mol Med"},{"key":"10.2515\/therapie\/2010055_bb0210","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0278-5846(03)00124-6","article-title":"Inflammatory processes in Alzheimer\u2019s disease","volume":"27","author":"McGeer","year":"2003","journal-title":"Neuropsychopharmacol Biol Psychiatry"},{"key":"10.2515\/therapie\/2010055_bb0215","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000078501","article-title":"Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer\u2019s disease: a systematic review","volume":"23","author":"Szekely","year":"2004","journal-title":"Neuroepidemiology"},{"key":"10.2515\/therapie\/2010055_bb0220","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","article-title":"Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial","volume":"289","author":"Aisen","year":"2003","journal-title":"JAMA"},{"key":"10.2515\/therapie\/2010055_bb0225","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(00)03155-X","article-title":"Statins and the risk of dementia","volume":"356","author":"Jick","year":"2000","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2010055_bb0230","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0896-6273(03)00840-7","article-title":"Cholesterol and the biology of Alzheimer\u2019s disease","volume":"41","author":"Wolozin","year":"2004","journal-title":"Neuron"},{"key":"10.2515\/therapie\/2010055_bb0235","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Sheperd","year":"2000","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2010055_bb0240","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"Heart protection study of cholesterol lowering with simvastatin in 20536 high risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group MRC\/BHF","year":"2002","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2010055_bb0245","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1212\/01.WNL.0000142963.90204.58","article-title":"Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study","volume":"63","author":"Li","year":"2004","journal-title":"Neurology"},{"key":"10.2515\/therapie\/2010055_bb0250","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1600-0404.2006.00687.x","article-title":"Re-assessing the relationship between cholesterol, statins and Alzheimer\u2019s disease","volume":"185","author":"Wolozin","year":"2006","journal-title":"Acta neurol Scand Suppl"},{"key":"10.2515\/therapie\/2010055_bb0255","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/jama.285.11.1489","article-title":"Hormone replacement therapy and cognition. Systematic review and meta-analysis","volume":"285","author":"LeBlanc","year":"2001","journal-title":"JAMA"},{"key":"10.2515\/therapie\/2010055_bb0260","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003122","article-title":"Hormone replacement therapy to maintain cognitive function in women with dementia","volume":"3","author":"Hogervorst","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.2515\/therapie\/2010055_bb0265","first-page":"1007","article-title":"Estrogen replacement therapy for treatment of mild to moderate Alzheimer\u2019s disease: a randomized controlled trial","volume":"283","author":"Mulnard","year":"2000","journal-title":"Alzheimer\u2019s Disease Cooperative Study. JAMA"},{"key":"10.2515\/therapie\/2010055_bb0270","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.291.24.2947","article-title":"Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenepausal women: Women Health Initiative Memory Study","volume":"291","author":"Shumaker","year":"2004","journal-title":"JAMA"},{"key":"10.2515\/therapie\/2010055_bb0275","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1001\/jama.287.24.3223","article-title":"Dietary intake of antioxydants and risk of Alzheimer disease","volume":"287","author":"Engelhart","year":"2004","journal-title":"JAMA"},{"key":"10.2515\/therapie\/2010055_bb0280","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1001\/jama.287.24.3230","article-title":"Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study","volume":"287","author":"Morris","year":"2002","journal-title":"JAMA"},{"key":"10.2515\/therapie\/2010055_bb0285","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJM199704243361704","article-title":"A controlled trial of selegiline, alphatocopherol or both as a treatment for Alzheimer\u2019s disease","volume":"336","author":"Sano","year":"1997","journal-title":"N Eng J Med"},{"key":"10.2515\/therapie\/2010055_bb0290","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa050151","article-title":"Vitamin E and donepezil for the treatment of mild cognitive impairment","volume":"352","author":"Petersen","year":"2005","journal-title":"N Eng J Med"},{"key":"10.2515\/therapie\/2010055_bb0295","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11886-003-0104-2","article-title":"Hypertension and dementia","volume":"6","author":"Hanon","year":"2003","journal-title":"Curr Cardiol Rep"},{"key":"10.2515\/therapie\/2010055_bb0300","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(96)90608-X","article-title":"15-year longitudinal study of blood pressure and dementia","volume":"347","author":"Skoog","year":"1996","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2010055_bb0305","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(98)03086-4","article-title":"Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial","volume":"352","author":"Forette","year":"1998","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2010055_bb0310","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1001\/archinte.162.18.2046","article-title":"The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-eur) study","volume":"162","author":"Forette","year":"2002","journal-title":"Arch Int Med"},{"key":"10.2515\/therapie\/2010055_bb0315","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/archinte.163.9.1069","article-title":"PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease","volume":"163","author":"Tzourio","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.2515\/therapie\/2010055_bb0320","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/archinte.161.2.152","article-title":"Blood pressure, cognitive function, and prevention of dementia in older patients with hypertension","volume":"161","author":"Birkenh\u00e4ger","year":"2001","journal-title":"Arch Int Med"},{"key":"10.2515\/therapie\/2010055_bb0325","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1097\/01.hjh.0000244961.69985.05","article-title":"Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints","volume":"1","author":"Hanon","year":"2006","journal-title":"J Hypertens"},{"key":"10.2515\/therapie\/2010055_bb0330","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1001\/archneur.60.7.940","article-title":"Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease","volume":"60","author":"Morris","year":"2003","journal-title":"Arch Neurol"},{"key":"10.2515\/therapie\/2010055_bb0335","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1046\/j.1532-5415.2003.51170.x","article-title":"Fitness and cognition: encouraging findings and methodological considerations for future work","volume":"51","author":"Simonsick","year":"2003","journal-title":"J Am Geriatr Soc"},{"key":"10.2515\/therapie\/2010055_bb0340","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1056\/NEJMoa022252","article-title":"Leisure activities and the risk of dementia in the elderly","volume":"348","author":"Verghese","year":"2003","journal-title":"N Engl J Med"},{"key":"10.2515\/therapie\/2010055_bb0345","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1056\/NEJMp030051","article-title":"Use it or lose it -do effortful mental activities protect against dementia?","volume":"348","author":"Coyle","year":"2003","journal-title":"N Engl J Med"},{"key":"10.2515\/therapie\/2010055_bb0350","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(94)92338-8","article-title":"Differences in the pattern of hippocampal neuronal loss in normal aging and Alzheimer disease","volume":"344","author":"West","year":"1994","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2010055_bb0355","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm1239","article-title":"A phase I clinical trial of nerve growth factor gene therapy for Alzheimer disease","volume":"11","author":"Tuszynski","year":"2005","journal-title":"Nat Med"},{"key":"10.2515\/therapie\/2010055_bb0360","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/WAD.0b013e318068d6d2","article-title":"Nerve growth factor gene therapy in Alzheimer disease","volume":"21","author":"Tuszynski","year":"2007","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.2515\/therapie\/2010055_bb0365","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1042\/CS20050161","article-title":"Clinical relevance of the neurotrophins and their receptors","volume":"110","author":"Allen","year":"2006","journal-title":"Clin Sci (Lond)"},{"key":"10.2515\/therapie\/2010055_bb0370","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jpsychores.2006.07.017","article-title":"Altered neurogenesis in Alzheimer\u2019s disease","volume":"61","author":"Ziabreva","year":"2006","journal-title":"J Psychosom Res"},{"key":"10.2515\/therapie\/2010055_bb0375","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(08)61074-0","article-title":"Effect of dimebon on cognition, activities of daily living, behaviour and global function in patients with mild-to-moderate Alzheimer\u2019s disease: a randomised, double-blind, placebocontrolled study","volume":"372","author":"Doody","year":"2008","journal-title":"Lancet"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T07:39:46Z","timestamp":1554277186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716307090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0040595716307090"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2010055","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}